US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

GRACE THERAPEUTICS INC

3.04

+0.325011.99%

Post-market: 3.090.0536+1.77%17:31 EDT

Volume:52.00K

Turnover:153.83K

Market Cap:41.63M

PE:-2.61

High:3.09

Open:2.79

Low:2.72

Close:2.71

Loading ...

Overview Company News Filings

TD Cowen Initiates Coverage on Grace Therapeutics With Buy Rating, $12 Price Target

MT Newswires Live

BRIEF-Grace Therapeutics Announces Alignment With The FDA Supporting The Submission For Gtx-104

Grace Therapeutics, Inc: Anticipates Filing Its Nda for Gtx-104 in Q2 of 2025

THOMSON REUTERS

Grace Therapeutics Announces Alignment With the FDA Supporting the Planned Nda Submission for Gtx-104

THOMSON REUTERS

BRIEF-Grace Therapeutics to offer up to 8.8 mln shares by selling stockholders, SEC Filing shows

Grace Therapeutics, Inc Files for Shelf of up to up to 8.8 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS

GRCE: STRIVE-ON Results Reported

Zacks Small Cap Research

Grace Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Grace Therapeutics, Inc - Q3 Shr Loss $0.36

THOMSON REUTERS

Grace Therapeutics Q3 EPS $(0.36) Vs $(0.34) Estimate

Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million

MT Newswires Live

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Grace Therapeutics announces private placement financing of up to $30M

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

THOMSON REUTERS

Grace Therapeutics, Inc - Proceeds to Fund Pre-Commercial Development of Gtx-104

THOMSON REUTERS

Grace Therapeutics, Inc - Nda Submission for Gtx-104 Expected in First Half of 2025

THOMSON REUTERS

Grace Therapeutics Announces Results From Pivotal Phase 3 Strive-on Safety Trial of Gtx-104 in Asah

THOMSON REUTERS

Grace Therapeutics, Inc - Phase 3 Trial Meets Primary Endpoint

THOMSON REUTERS

Craig-Hallum Reaffirms Their Buy Rating on Grace Therapeutics (GRCE)

3 US Penny Stocks With Market Cap Under $70M

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GRCE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRCE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRCE\",,,,,undefined,":{"symbol":"GRCE","market":"US","secType":"STK","nameCN":"GRACE THERAPEUTICS INC","latestPrice":3.035,"timestamp":1746216000000,"preClose":2.71,"halted":0,"volume":51996,"hourTrading":{"tag":"盘后","latestPrice":3.0886,"preClose":3.035,"latestTime":"17:31 EDT","volume":118,"amount":363.53,"timestamp":1746221518602},"delay":0,"floatShares":4952340,"shares":13718106,"eps":-1.162341,"marketStatus":"Market Closed","change":0.325,"latestTime":"05-02 16:00:00 EDT","open":2.79,"high":3.09,"low":2.7215,"amount":153828.970092,"amplitude":0.135978,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.162341,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"listingDate":1357534800000,"exchange":"NASDAQ","adjPreClose":2.71,"postHourTrading":{"tag":"盘后","latestPrice":3.0886,"preClose":3.035,"latestTime":"17:31 EDT","volume":118,"amount":363.53,"timestamp":1746221518602},"volumeRatio":4.4219225452006645},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRCE\",,,,,undefined,":{"symbol":"GRCE","floatShares":4952340,"roa":"-15.16%","roe":"-22.89%","lyrEps":-1.348812,"volumeRatio":4.4219225452006645,"shares":13718106,"dividePrice":0,"high":3.09,"amplitude":0.135978,"preClose":2.71,"low":2.7215,"week52Low":1.75,"pbRate":"0.80","week52High":4.965,"institutionHeld":0,"latestPrice":3.035,"eps":-1.162341,"divideRate":0,"volume":51996,"delay":0,"ttmEps":-1.162341,"open":2.79,"prevYearClose":3.74,"prevWeekClose":2.49,"prevMonthClose":2.61,"prevQuarterClose":2.28,"fiveDayClose":2.49,"twentyDayClose":2.2,"sixtyDayClose":3.3989},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GRCE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532720817","title":"TD Cowen Initiates Coverage on Grace Therapeutics With Buy Rating, $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2532720817","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532720817?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:30","pubTimestamp":1746185430,"startTime":"0","endTime":"0","summary":"Grace Therapeutics, Inc. (GRCE) has an average rating of Buy and mean price target of $11.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TD","COWN","GRCE","LENZ"],"gpt_icon":0},{"id":"2526736317","title":"BRIEF-Grace Therapeutics Announces Alignment With The FDA Supporting The Submission For Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2526736317","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526736317?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:13","pubTimestamp":1744200815,"startTime":"0","endTime":"0","summary":"BRIEF-Grace Therapeutics Announces Alignment With The FDA Supporting The Submission For Gtx-104April 9 (Reuters) - Grace Therapeutics, Inc GRCE.O:GRACE THERAPEUTICS ANNOUNCES ALIGNMENT WITH THE FDA SU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN07P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2526368293","title":"Grace Therapeutics, Inc: Anticipates Filing Its Nda for Gtx-104 in Q2 of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526368293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526368293?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:00","pubTimestamp":1744200019,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN07P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2526368257","title":"Grace Therapeutics Announces Alignment With the FDA Supporting the Planned Nda Submission for Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2526368257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526368257?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:00","pubTimestamp":1744200019,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN07P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2518221085","title":"BRIEF-Grace Therapeutics to offer up to 8.8 mln shares by selling stockholders, SEC Filing shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2518221085","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518221085?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:26","pubTimestamp":1741613193,"startTime":"0","endTime":"0","summary":"BRIEF-Grace Therapeutics to offer up to 8.8 mln shares by selling stockholders, SEC Filing showsMarch 10 (Reuters) - Grace Therapeutics, Inc GRCE.O:GRACE THERAPEUTICS, INC FILES FOR SHELF OF UP TO UP ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2518228383","title":"Grace Therapeutics, Inc Files for Shelf of up to up to 8.8 Mln Shares of Common Stock by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2518228383","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518228383?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:59","pubTimestamp":1741607955,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2513963232","title":"GRCE: STRIVE-ON Results Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2513963232","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513963232?lang=en_us&edition=fundamental","pubTime":"2025-02-21 17:40","pubTimestamp":1740130800,"startTime":"0","endTime":"0","summary":"Grace Therapeutics, Inc  reported fiscal year  third quarter results following a series of announcements regarding conference participation, the raise of additional capital and results from the Phase III STRIVE-ON trial for GTx-104. The most important information was the data from the Phase III safety trial. In patients, it found excellent relative dose intensity, better outcomes, fewer intensive care unit readmissions and fewer ventilator days for GTx-104 compared with oral nimodipine. Following the data release, Grace executed a capital raise to fund pre-commercial development of GTx-104.Grace reported third quarter fiscal year 2025 results in a press release and Form 10-Q filing with the SEC on February 13th. For the quarter ending December 31, 2024, operating expenses of $3.7 million were recognized. Net loss for 3Q:25 totaled  million or  per share. For FY 3Q:25 versus the same prior year period:. General & Administrative expenses were $1.5 million, down 4% from $1.6 million attri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grce-strive-results-reported-094000032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2357305700.SGD","LU0724618433.USD","GRCE","LU1854103824.USD","LU0348723411.USD","BK4108","IE00BZ199S13.USD","LU1861215975.USD","ICU","BK4512","LU0124384867.USD","BK4605","ON","LU1720051017.SGD","LU1548497426.USD","LU1861219969.SGD","BK4588","BK4007","LU1861220033.SGD","LU2298322129.HKD","BK4141","BK4082","LU2360107325.USD","LU1861214812.USD","RDI","LU1854104046.USD","LU1720051108.HKD","IE00BD6J9T35.USD","LU1978683503.SGD","BK4585"],"gpt_icon":0},{"id":"2512156579","title":"Grace Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2512156579","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512156579?lang=en_us&edition=fundamental","pubTime":"2025-02-18 19:47","pubTimestamp":1739879220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GRCE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 06:47 ET (11:47 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","LENZ"],"gpt_icon":0},{"id":"2511017542","title":"Grace Therapeutics, Inc - Q3 Shr Loss $0.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2511017542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511017542?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:13","pubTimestamp":1739452424,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P41XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2511424875","title":"Grace Therapeutics Q3 EPS $(0.36) Vs $(0.34) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2511424875","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511424875?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:07","pubTimestamp":1739452029,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Q3 EPS $(0.36) Vs $(0.34) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43691440/grace-therapeutics-q3-eps-0-36-vs-0-34-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","GRCE"],"gpt_icon":0},{"id":"2510497896","title":"Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2510497896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510497896?lang=en_us&edition=fundamental","pubTime":"2025-02-11 02:44","pubTimestamp":1739213048,"startTime":"0","endTime":"0","summary":"Grace Therapeutics  rose nearly 8% in recent Monday trading after it said it entered into securities purchase agreements for a private placement financing of up to $30 million with healthcare-focused institutional investors.The financing consists of an initial upfront funding of about $15 million, with an additional potential $15 million if accompanying warrants are exercised for cash. The deal is expected to close on Tuesday, subject to customary closing conditions.As part of the financing, Grace Therapeutics will issue about 4.4 million common shares, or pre-funded warrants in lieu thereof, along with warrants to purchase up to an additional 4.4 million shares at a combined purchase price of $3.395 per share.Each warrant allows the holder to purchase one share at $3.395 and will expire either 60 days after the US Food and Drug Administration approves the New Drug Application for GTx-104 or on Sept. 25, 2028.If all warrants are exercised, Grace Therapeutics could receive up to $15 mil","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRCE","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2510898033","title":"Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2510898033","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510898033?lang=en_us&edition=fundamental","pubTime":"2025-02-11 01:05","pubTimestamp":1739207159,"startTime":"0","endTime":"0","summary":"On Monday, Grace Therapeutics, Inc. , formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 compared with oral nimodipinein patients hospitalized with aneurysmal Subarachnoid Hemorrhage .aSAH is bleeding over the brain’s surface in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain.The study met its primary endpoint and provides evidence of clinical benefit compared to orally administered nimodipine.The trial met its primary endpoint, with patients receiving GTx-104 observed to have a 19% reduction in at least one incidence of clinically significant hypotension compared to oral nimodipine . Other measures also favored or were comparable to GTx-104, including:. 54% of patients who received GTx-104 had a relative dose intensity  of 95% or higher of the prescribed dose compared to only 8% on oral nimodipine.29% relative increase in the number of patients receiving GTx-104 compared to oral nimodipine wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/small-cap-grace-therapeutics-touts-170559950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4108","GRCE","ICU","LENZ","BK4007","BK4082","RDI"],"gpt_icon":0},{"id":"2510852409","title":"Grace Therapeutics announces private placement financing of up to $30M","url":"https://stock-news.laohu8.com/highlight/detail?id=2510852409","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510852409?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:25","pubTimestamp":1739193953,"startTime":"0","endTime":"0","summary":"Grace Therapeutics (GRCE) announced that it has entered into securities purchase agreements with new and existing healthcare focused institutional ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grace-therapeutics-announces-private-placement-financing-of-up-to-30m?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grace-therapeutics-announces-private-placement-financing-of-up-to-30m?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GRCE","LENZ","BK4007"],"gpt_icon":0},{"id":"2510854642","title":"Grace Therapeutics Announces Private Placement Financing of up to $30 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2510854642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510854642?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:05","pubTimestamp":1739192700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUABRKQ7K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2510854628","title":"Grace Therapeutics, Inc - Proceeds to Fund Pre-Commercial Development of Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2510854628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510854628?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:05","pubTimestamp":1739192700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUABRKQ7K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2510854899","title":"Grace Therapeutics, Inc - Nda Submission for Gtx-104 Expected in First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2510854899","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510854899?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:01","pubTimestamp":1739192460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA6LWV4Q:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2510854851","title":"Grace Therapeutics Announces Results From Pivotal Phase 3 Strive-on Safety Trial of Gtx-104 in Asah","url":"https://stock-news.laohu8.com/highlight/detail?id=2510854851","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510854851?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:01","pubTimestamp":1739192460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA6LWV4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2510385100","title":"Grace Therapeutics, Inc - Phase 3 Trial Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2510385100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510385100?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:01","pubTimestamp":1739192460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA6LWV4Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2506519260","title":"Craig-Hallum Reaffirms Their Buy Rating on Grace Therapeutics (GRCE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2506519260","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506519260?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:16","pubTimestamp":1738073802,"startTime":"0","endTime":"0","summary":"In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Grace Therapeutics (GRCE – Research Report). The compa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-grace-therapeutics-grce-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-grace-therapeutics-grce-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRCE"],"gpt_icon":0},{"id":"2505041325","title":"3 US Penny Stocks With Market Cap Under $70M","url":"https://stock-news.laohu8.com/highlight/detail?id=2505041325","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505041325?lang=en_us&edition=fundamental","pubTime":"2025-01-24 01:09","pubTimestamp":1737652143,"startTime":"0","endTime":"0","summary":"As the S&P 500 edges toward new highs amidst mixed trading sessions, investors are paying close attention to smaller market segments for potential opportunities. Penny stocks, though an older term, continue to represent a compelling area of interest due to their association with smaller or emerging companies that might offer significant growth potential. By focusing on those with strong financials and solid fundamentals, investors can find unique opportunities in this often-overlooked segment of the market.Overview: Grace Therapeutics, Inc. focuses on developing and commercializing pharmaceutical products for rare and orphan diseases in Canada, with a market cap of $37.72 million.Generation Bio Co., with a market cap of US$66.12 million, is pre-revenue and focuses on genetic medic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-us-penny-stocks-market-170903078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","GBIO","SB","BABB","BK4209","BK4584","BK4139","GRCE","BK4021"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRCE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-13","symbol":"GRCE","fiscalQuarterEnding":"2024/12","expectedEps":-0.24,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1739422800000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2024-11-13","symbol":"GRCE","fiscalQuarterEnding":"2024/09","expectedEps":-0.33,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.33},{"market":"US","date":"2024-08-09","symbol":"GRCE","fiscalQuarterEnding":"2024/06","expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"pre","actualEps":-0.24},{"market":"US","date":"2024-06-21","symbol":"GRCE","fiscalQuarterEnding":"2024/03","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1718942400000,"reportTimeType":"pre","actualEps":-0.18},{"market":"US","date":"2024-02-12","symbol":"GRCE","fiscalQuarterEnding":"2023/12","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1707714000000,"reportTimeType":"pre","actualEps":-0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRCE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRCE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1739937600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GRCE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GRCE","date":"2025-05-01","current":-2.677955,"percent":0.577236,"low":-3.931533,"twenty":-3.244825,"median":-2.756442,"eighty":-2.201874,"high":-1.653321,"avg":-2.732583,"sd":0.544635,"marketCap":35804256},"quantilePoints":[{"date":"2024-10-31","current":-2.746009,"twenty":-2.84522,"median":-2.808016,"eighty":-2.770812,"marketCap":31433569},{"date":"2024-11-08","current":-2.737151,"twenty":-2.770812,"median":-2.746009,"eighty":-2.701719,"marketCap":31332170},{"date":"2024-11-15","current":-2.891861,"twenty":-2.815988,"median":-2.74158,"eighty":-2.694633,"marketCap":33562939},{"date":"2024-11-22","current":-2.821967,"twenty":-2.824979,"median":-2.746009,"eighty":-2.701719,"marketCap":32751751},{"date":"2024-11-29","current":-2.935545,"twenty":-2.870023,"median":-2.76081,"eighty":-2.701719,"marketCap":34069932},{"date":"2024-12-06","current":-3.791745,"twenty":-2.935545,"median":-2.823849,"eighty":-2.717126,"marketCap":44006996},{"date":"2024-12-13","current":-3.407329,"twenty":-3.407329,"median":-2.865651,"eighty":-2.737151,"marketCap":39545457},{"date":"2024-12-20","current":-3.547117,"twenty":-3.407329,"median":-2.887493,"eighty":-2.746009,"marketCap":41167835},{"date":"2024-12-27","current":-3.232594,"twenty":-3.39335,"median":-2.931176,"eighty":-2.746009,"marketCap":37517485},{"date":"2025-01-03","current":-3.494696,"twenty":-3.396845,"median":-2.953018,"eighty":-2.749647,"marketCap":40559444},{"date":"2025-01-10","current":-3.582064,"twenty":-3.494696,"median":-3.066596,"eighty":-2.755568,"marketCap":41573430},{"date":"2025-01-17","current":-2.935545,"twenty":-3.494696,"median":-3.057859,"eighty":-2.767291,"marketCap":34069932},{"date":"2025-01-24","current":-3.437907,"twenty":-3.492949,"median":-3.145227,"eighty":-2.786004,"marketCap":39900353},{"date":"2025-01-31","current":-2.778283,"twenty":-3.476349,"median":-3.13649,"eighty":-2.78702,"marketCap":32244757},{"date":"2025-02-07","current":-2.918071,"twenty":-3.433539,"median":-3.040386,"eighty":-2.785272,"marketCap":33867135},{"date":"2025-02-14","current":-3.040386,"twenty":-3.416065,"median":-3.038201,"eighty":-2.814977,"marketCap":35286716},{"date":"2025-02-21","current":-2.570989,"twenty":-3.416065,"median":-3.009807,"eighty":-2.777013,"marketCap":34374128},{"date":"2025-02-28","current":-2.29038,"twenty":-3.407329,"median":-2.996702,"eighty":-2.746009,"marketCap":30622380},{"date":"2025-03-07","current":-2.050724,"twenty":-3.407329,"median":-2.952538,"eighty":-2.701719,"marketCap":27418184},{"date":"2025-03-14","current":-1.736745,"twenty":-3.389855,"median":-2.935545,"eighty":-2.613138,"marketCap":23220281},{"date":"2025-03-21","current":-1.941514,"twenty":-3.363645,"median":-2.904966,"eighty":-2.495149,"marketCap":25958044},{"date":"2025-03-28","current":-2.329102,"twenty":-3.337435,"median":-2.883124,"eighty":-2.329102,"marketCap":31140100},{"date":"2025-04-04","current":-2.25728,"twenty":-3.328698,"median":-2.865651,"eighty":-2.3283,"marketCap":30179833},{"date":"2025-04-11","current":-1.99051,"twenty":-3.319961,"median":-2.825732,"eighty":-2.29038,"marketCap":26613125},{"date":"2025-04-17","current":-2.093114,"twenty":-3.278025,"median":-2.81323,"eighty":-2.187348,"marketCap":27984936},{"date":"2025-04-25","current":-2.441966,"twenty":-3.253562,"median":-2.777648,"eighty":-2.187348,"marketCap":32649092},{"date":"2025-05-01","current":-2.677955,"twenty":-3.244825,"median":-2.756442,"eighty":-2.201874,"marketCap":35804256}],"updateTime":1746225623756}}}